SPY330.65-3.85 -1.15%
DIA276.52-2.38 -0.85%
IXIC10,793.28-117.00 -1.07%

INmune Bio Highlights Presentation Of Study Showing Combo Of INB03 With Lapatinib Reverses Resistance To Therapy In Trastuzumab Resistant HER2+ Breast Cancer

INmune Bio, Inc. (NASDAQ:INMB) (the “Company”), a clinical-stage immunology company focused on  developing treatments that harness the patient’s innate immune system to fight disease, announced

Benzinga · 05/11/2020 13:10

INmune Bio, Inc. (NASDAQ:INMB) (the “Company”), a clinical-stage immunology company focused on  developing treatments that harness the patient’s innate immune system to fight disease, announced presentation of a study  demonstrating the combination of INB03 with lapatinib reverses resistance to therapy in trastuzumab resistant HER2+ breast cancer.  The work lays the groundwork for INmune Bio’s planned Phase II trial and, was chosen for an oral presentation at the New York Academy of Science Frontiers in Cancer Immunotherapy 2020 publication on Monday, 11 May.  Sophi Bruni, a doctoral student in the laboratory of Dr. Roxana Schillaci, in the Lab of Molecular Mechanisms, Instituto de Biología y Medicina Experimental-CONICET, Argentina will be presenting the work. 

This presentation is part of the evolving body of work by Dr. Schillaci and her team in the role of soluble TNF in resistance to immunotherapies in cancer.  Dr. Schillaci previously reported that women with MUC4 expressing HER2+ breast cancers are resistant to trastuzumab and downregulation of MUC4 with INB03 reversed trastuzumab resistance. This work is part of a larger body of work looking at reversal of resistance to tyrosine kinase inhibitors in HER2+ breast cancer.

“Previous work by Dr. Schillaci suggests soluble TNF plays an important role in causing trastuzumab resistance in women with HER2+ breast cancer,” said RJ Tesi MD, Chief Executive Officer of INmune Bio. “This work provides the therapeutic combination that fits neatly into the standard-of-care and may benefit women with brain metastasis caused by HER2 positive breast cancer.”

“For the last two decades, trastuzumab administration as first line in HER2+ breast cancer has positively changed the prognosis of patients.  However, in the metastatic setting, this disease is still life-threatening.” said Dr. Schillaci. “Our previous work suggested MUC4 inhibited trastuzumab by steric hinderance.  This work shows the mechanism is more interesting and involves intracellular mechanisms.”  

Dr. Schillaci’s work in defining the role of soluble TNF in trastuzumab resistance in women with HER2+ breast cancer is the basis for INMB’s planned Phase II trial in women with metastatic HER2+ breast cancer.